SPOTLIGHT: Study questions Medtronic stent

Ahead of next week's FDA panel review of Medtronic's new Endeavor stent, the agency released documents questioning its effectiveness; the company's stock dipped 2 percent on the news. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?